Skip to main content

Affy Says Sales Surpassed $100M in Q4 04, a 17-Percent Increase

NEW YORK, Jan. 5 (GenomeWeb News) - Affymetrix estimates it has generated more than $100 million in product-related revenues for the fourth quarter of 2004, a record for the company, the firm said today.


This represents a 17-percent increase over the $85.3 million in product-related revenues recorded for the same quarter a year ago.


Affymetrix also said it has $10 million worth of orders for products it plans to release within the next six months, including new SNP-genotyping arrays and automated instrumentation.


The company will release its formal financial results on Jan. 26 after the stock market closes.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.